[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 5 sources · 8 days · First seen · Last updated

Global generic production of baloxavir marboxil

Overview

A voluntary licensing agreement between Roche and the Medicines Patent Pool (MPP) is facilitating the production of generic versions of the antiviral influenza treatment, baloxavir marboxil. This initiative aims to supply the medicine to 129 low- and middle-income countries to improve pandemic preparedness and expand treatment access.

In late September 2026, Uganda’s Quality Chemical Industries Limited (Qcil) signed a sublicence agreement to develop and supply the generic drug. Following this, Fidson Healthcare Plc in Nigeria was identified as one of 11 global manufacturers selected for the program. Other participating nations include Brazil, China, India, Indonesia, Malaysia, Ukraine, and Vietnam. The program provides manufacturers with technical data to build a geographically resilient supply base before future health emergencies occur.

Entities

Medicines Patent Pool · Roche · World Health Organization · Quality Chemical Industries Limited · baloxavir marboxil

Timeline

  1. [HEALTH] 2 sources
    Fidson Healthcare to manufacture generic Roche influenza drug

    Fidson Healthcare Plc will manufacture generic versions of Roche’s influenza drug, baloxavir marboxil, under a Medicines Patent Pool agreement to expand access across 129 countries.

  2. [HEALTH] 3 sources
    Quality Chemical Industries to produce generic influenza treatment

    Ugandan manufacturer Qcil will develop a generic version of the influenza antiviral baloxavir marboxil to expand access across 129 low- and middle-income countries.

Sources

businessday.ng · riotimesonline.com · sanyufm.com · thisdaylive.com · ugbulletin.co.ug